LTRN
Lantern Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$19.81M
P/E Ratio
—
EPS
$-1.57
Beta
1.75
52W High
$5.74
52W Low
$1.11
50-Day MA
$2.55
200-Day MA
$3.53
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lantern Pharma Inc
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.96M |
| Operating Margin | 0.00% |
| Return on Equity | -123.50% |
| Return on Assets | -61.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.58 |
| Price-to-Book | 2.79 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $11.25M |
| Float | $8.76M |
| % Insiders | 13.52% |
| % Institutions | 19.84% |
Analyst Ratings
Consensus ($20.00 target)
2
BuyData last updated: 4/8/2026